Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta

Autor: Joan-Carles Arce, Bernadette Mannaerts, Esther, Jon Havelock, Esther Trial Groups, Anna-Karina Aaris Henningsen
Rok vydání: 2021
Předmět:
Adult
Male
0301 basic medicine
endocrine system
Fresh cycle
Follitropin delta
Adolescent
Pregnancy Rate
Denmark
Stimulation
Fertilization in Vitro
Andrology
Young Adult
03 medical and health sciences
0302 clinical medicine
Ovulation Induction
Pregnancy
Genetics
Humans
Medicine
Embryo Implantation
Take-home baby rate
Assisted Reproduction Technologies
Genetics (clinical)
030219 obstetrics & reproductive medicine
business.industry
Infant
Newborn
Pregnancy Outcome
Obstetrics and Gynecology
General Medicine
Neonatal outcome
Comparative trial
Follitropin alfa
medicine.disease
Start up
Recombinant Proteins
Blastocyst
Frozen cycle
030104 developmental biology
Reproductive Medicine
Neonatal outcomes
Female
Follicle Stimulating Hormone
Human
Ovarian stimulation
business
Live Birth
Developmental Biology
Zdroj: Journal of Assisted Reproduction and Genetics
ISSN: 1573-7330
1058-0468
Popis: Purpose To describe the pregnancy and neonatal outcomes using fresh and vitrified/warmed blastocysts obtained from ovarian stimulation with follitropin delta in controlled trials versus follitropin alfa. Methods This investigation evaluated the outcome from 2719 fresh and frozen cycles performed in 1326 IVF/ICSI patients who could start up to three ovarian stimulations in the ESTHER-1 (NCT01956110) and ESTHER-2 (NCT01956123) trials, covering 1012 fresh cycles and 341 frozen cycles with follitropin delta and 1015 fresh cycles and 351 frozen cycles with follitropin alfa. Of the 1326 first cycle patients, 513 continued to cycle 2 and 188 to cycle 3, and 441 patients started frozen cycles after the fresh cycles. Pregnancy follow-up was continued until 4 weeks after birth. Results The overall cumulative take-home baby rate after up to three stimulation cycles was 60.3% with follitropin delta and 60.7% with follitropin alfa (−0.2% [95% CI: −5.4%; 5.0%]), of which the relative contribution was 72.8% from fresh cycles and 27.2% from frozen cycles in each treatment group. Across the fresh cycles, the ongoing implantation rate was 32.1% for follitropin delta and 32.1% for follitropin alfa, while it was 27.6% and 27.8%, respectively, for the frozen cycles. Major congenital anomalies among the live-born neonates up until 4 weeks were reported at an incidence of 1.6% with follitropin delta and 1.8% with follitropin alfa (−0.2% [95% CI: −1.9%; 1.5%]). Conclusions Based on comparative trials, the pregnancy and neonatal outcomes from fresh and frozen cycles provide reassuring data on the efficacy and safety of follitropin delta. Trial registration ClinicalTrials.gov Identifier: NCT01956110 registered on 8 October 2013; NCT01956123 registered on 8 October 2013.
Databáze: OpenAIRE
Externí odkaz: